Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why 23andMe Stock Tumbled 10% on Tuesday

TheMotleyFool 
0 0 04.06.24
Why 23andMe Stock Tumbled 10% on Tuesday
 

Genetic database builder 23andMe (NASDAQ: ME) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety. The company announced a collaboration with the nonprofit Colorectal Cancer Alliance "to help advance research on colorectal cancer in the Black/African American community."

Now, why might investors consider this bad news for 23andMe stock?

Let's start with the obvious: 23andMe is partnering with a non-profit organization, on a project that will have it sign up individuals "to help fill in the gap ... [in] research on colorectal cancer in the Black community." Presumably, the individuals recruited will all get genetic tests with 23andMe, but they will receive "the option to access health reports through a 23andMe+ Premium membership at no cost."

Continue reading


Source Fool.com

Genetic Technologies Ltd. Stock

€0.020
-2.500%
A loss of -2.500% shows a downward development for Genetic Technologies Ltd..

Show more
Like: 0
ME
Share

Comments

Not a member yet? Sign up for free!